Mersana Therapeutics, Inc. Awarded Patent With Broad Coverage For Fleximer-ADC Platform Technology
4/2/2014 9:55:20 AM
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Mersana Therapeutics, Inc., a biopharmaceutical company developing its Fleximer® antibody-drug conjugate (ADC) platform and therapeutics, today announced that it was awarded U.S. Patent No. 8,685,383, entitled “Protein-Polymer-Drug Conjugates.” This patent provides Mersana broad coverage for its polymer-based Fleximer-ADC platform technology. The patent covers Fleximer-drug conjugates that can be linked to an antibody to create next-generation antibody drug conjugates.
Help employers find you! Check out all the jobs and post your resume.
comments powered by